MacroCure Ltd is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers.
The company's approach is to treat chronic and other hard-to-heal wounds by injecting the human body's own wound-healing and regenerative components directly into the wound. MacroCure's lead product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.
CureXcell's two phase 3 double-blind clinical trials target a broad indication for the treatment of diabetic foot ulcers and venous leg ulcers. MacroCure already has product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds. CureXcell has effectively treated more than 5,000 patients in commercial or clinical study settings in Israel.
In 2017, MacroCure Ltd merged into Leap Therapeutics, Inc.